Index

abdominal pain, 159–160
Abilify. See aripiprazole
abstinence, motivation for, 144–145
acamprosate, 138–139
accountable practice, 7, 237
acetaminophen, 165, 167
action, 229
acute depression, 63, 66–67
acute mania, 63, 66–67
Adderall. See dextroamphetamine/amphetamine
Adderall XR. See dextroamphetamine/amphetamine
ER
ADHD. See attention-deficit hyperactivity disorder
adjustment disorder, 35, 84
adolescents
ADHD in, 181–183, 185, 188, 192–197, 200
depression in, 53
Advil. See ibuprofen
AEDs. See antiepileptic drugs
agonists, 140
alcohol use
disorders, 35, 124–128, 132–133, 135, 137–139, 144
harm reduction ideas for, 144
history, 8

suicide and, 128
withdrawal from, 137
alcohol-induced depressive disorder, 35
Aleve. See naproxen sodium
alprazolam (Xanax, Xanax XR), 90
prescribing protocols, 258–259
quick reference, 242
Ambien. See zolpidem
amitriptyline (Elavil), 42, 242
amphetamines, 141
agonists, 140–141
antianxiety medications
black-box warnings for, 258–264
dosing information for, 242–243, 258–264
in evidence-based psychopharmacology, 242–243, 258–264
monitoring of, 258–264
prescribing protocols for, 258–264
quick reference for, 242–243
side effects of, 258–264
anticonvulsants, 67
antidepressants, 38–41, 45–50, 65–66, 141
anxiety treatment and, 95
black-box warnings for, 247–257
chronic pain and, 165, 167, 169
antidepressants (continued)

dosing information for, 241–242, 247–257
in evidence-based psychopharmacology, 241–242, 247–257
monitoring of, 247–257
prescribing protocols for, 247–257
quick reference for, 241–242
serotonergic, 42, 87–88
side effects of, 42–43, 247–257
warnings/precautions for, 246

antiepileptic drugs (AEDs), 167–168

antipsychotics, 66–67
atypical, 48
dosing information for, 245–246, 275–277
monitoring of, 121, 276–280, 281, 283–285, 287, 289–290
prescribing protocols for, 275–291
in psychotic disorders treatment, 110–122
quick reference for, 245–246
side effects of, 102, 115–117, 276–283, 285–290

antisocial personality disorder, 186

anxiety and trauma disorders
assessment of, 78–81
behavioral interventions for, 86–87, 90–91, 94–95, 97–98, 233
BHP and, 80–81, 85, 91–94, 96–99
case example of, 80–81, 85, 97, 99
chief complaint of, 78
clinical impact of, 78
comorbid disorders with, 84, 108, 118
differential diagnosis and, 11, 34, 61, 81–85, 160, 186–187
follow-up and adjustment for, 94–97
functional impairments of, 79
goals for, 80, 84–85, 93, 96–97, 99
medication for, 87–90, 94–99, 242–243, 258–264
patient and, 80–81, 85, 93–94, 96–97, 99
PC and, 80, 85, 93–94, 97, 99
PCP and, 80–81, 85–99
physical/somatic symptoms of, 78–79
provisional diagnosis of, 81–85
psychoeducation about, 86
psychological symptoms of, 78–79
psychosocial interventions for, 87
referrals for, 94
relapse prevention of, 97–99
resources for, 99
safety and, 79–80, 86
types of, 79, 82–84

anxiolytics. See antianxiety medications Aplenzin. See bupropion

appointment times, extended, 213–214

aripiprazole (Abilify), 48, 111
    prescribing protocols, 275–277
    quick reference, 245
asenapine (Saphris), 111, 277–278

assessment
    of ADHD, 182–190
    of anxiety and trauma disorders, 78–81
    of bipolar disorder, 33, 56–58
    in challenging clinical situations, 209–210
    chief complaint identified in, 8–9
    of chronic pain, 154–158
    by Collaborative Care team, 8–15
    of comorbid disorders, 14
    in continuum of care, 228
differential diagnosis in, 8, 10–15
    goals, 9, 11–15
    of major depression, 28–31, 33
    measures, 8
    provisional diagnosis in, 10–15
    of psychotic disorders, 102–105
    for safety, 9, 13
    of substance-use disorders, 125–132
    for suicide, 9, 29–31
    of symptoms, 8, 11

Ativan. See lorazepam

atomoxetine (Strattera), 193–195, 264–265
Index 301

attention-deficit hyperactivity disorder (ADHD), 83, 89, 129
in adolescents, 181–183, 185, 188, 192–197, 200
assessment of, 182–190
behavioral interventions for, 191, 196–197, 233
BHP and, 184, 189–191, 196–202
case example of, 183–184, 189–190, 198–199, 201–202
chief complaint of, 182–184
clinical impact of, 181
common disorders of, 188
comorbid disorders with, 185
differential diagnosis of, 184–190
follow-up and adjustment for, 199–201
functional impairments of, 183
goals for, 183–184, 188–189, 198, 200, 202
medications, 191–196, 198–202, 264–269
patient and, 183–184, 188–190, 198–202
PC and, 184, 189, 198, 200–202
PCP and, 184, 188–196, 198–202
physical/somatic symptoms of, 183
provisional diagnosis of, 188–189
psychoeducation about, 190
psychological symptoms, 182–183
psychosocial interventions for, 191–192, 197
rating scales, 185
referrals for, 199
relapse prevention of, 201–202
resources for, 202
safety and, 192
stimulant use and, 191–194, 198–199
substance-use disorders and, 184, 191
treatment of, 190–202, 264–269
atypical antipsychotics, 48
augmentation strategies, 48, 65, 71
autism spectrum disorders, 187
avoidance, chronic pain and, 161
BA. See behavioral activation
back pain, 159–160, 167
behavioral activation (BA), 39, 44
behavioral health provider (BHP)
ADHD and, 184, 189–191, 196–202
anxiety and trauma disorders and, 80–81, 85, 91–94, 96–99
bipolar disorder and, 57–58, 62–63, 68–70, 72–74, 76
in challenging clinical situations, 217, 219
chronic pain and, 157–158, 162, 164–166, 170–173, 176–179
on Collaborative Care team, 2–5, 7, 9–10, 15, 17–23
core skills of, 227–229
distress tolerance strategies of, 231
evidence-based behavioral interventions and, 227–232, 236–237
evidence-based psychopharmacology and, 238
major depression and, 30–31, 36, 39, 44–47, 49–50, 52
measurement-based practice and, 19
psychotic disorders and, 105, 108–110, 112–113, 118–120, 122
substance-use disorders and, 130–131, 134–136, 143–146, 148–150
behavioral indicators, of substance-use disorders, 126
behavioral interventions. See also evidence-based behavioral interventions, for Collaborative Care team
for ADHD, 191, 196–197, 233
for anxiety and trauma disorders, 86–87, 90–91, 94–95, 97–98, 233
for bipolar disorder, 64–65, 69, 72, 233
in challenging clinical situations, 218–223
for chronic pain, 164, 166–170, 233
for major depression, 39–40, 44, 49, 233
overview of, 17
for psychotic disorders, 110, 112, 119, 121, 233
for substance-use disorders, 135, 141, 147, 233
benzodiazepines, 43, 75, 87–90, 139, 167
benztropine, 116
BHP. See behavioral health provider
biological treatment
for ADHD, 191
for anxiety and trauma disorders, 87
for bipolar disorder, 64
for chronic pain, 165
for major depression, 38
for psychotic disorders, 110
for substance-use disorders, 135
biopsychosocial model, of chronic pain, 163–164, 166
bipolar disorder
assessment of, 33, 56–58
behavioral interventions for, 64–65, 69, 72, 233
BHP and, 57–58, 62–63, 68–70, 72–74, 76
case example of, 58, 62, 72–73, 76
chief complaint of, 56
chronic diseases and, 55, 65
clinical impact of, 55
differential diagnosis and, 33–35, 58–63, 83, 186
follow-up and adjustment for, 71–74
functional impairments of, 57
goals for, 57, 62, 70, 72, 76
medication for, 64–76, 89, 245–246
patient and, 57–58, 62–63, 70, 72–73, 76
PC and, 57–58, 62, 70, 72–73, 76
PCP and, 57–58, 62, 66–68, 70–72, 76
physical/somatic symptoms of, 56–57
provisional diagnosis of, 58–63
psychoeducation about, 66
psychological symptoms of, 56
psychosocial interventions for, 64, 68–69, 75
with psychotic features, 107, 117
rapid cycling, 67
referrals for, 71
relapse prevention of, 74–76
resources for, 76–77
safety and, 57
substance-use disorders and, 58, 61
suicide and, 57
treatment of, 63–76, 89, 245–246
types of, 63, 74–75, 107
black-box warnings
for ADHD medications, 265–268
for antianxiety medications, 258–264
for antidepressants, 247–257
defined, 239
for hypnotic medications, 258–264
for miscellaneous medications, 269
for mood stabilizers, 270, 272–274
bond, 229–230
borderline personality disorder, 60
breastfeeding
psychosis and, 118
buprenorphine/naloxone (Suboxone), 138, 140
prescribing protocols, 247–248
quick reference, 241
buspirone (BuSpar), 88
prescribing protocols, 259–260
quick reference, 243
cannabis use
disorders, 124, 126–127, 129–130, 132, 141
harm reduction ideas for, 145
carbamazepine, 66–67
carbamazepine extended release (Equetro), 270–271
cardiovascular conditions
in anxiety differential diagnosis, 81
in major depression differential diagnosis, 32
QTC interval prolongation, 117
in substance-use disorder differential diagnosis, 133
care, continuum of, 227–228
care manager (CM), 1. See also behavioral health provider
carisoprodol (Soma), 167
case examples
ADHD, 183–184, 189–190, 198–199, 201–202
anxiety and trauma disorders, 80–81, 85, 97, 99
bipolar disorder, 58, 62, 72–73, 76
challenging clinical situations, 207, 217–218, 222, 224
Collaborative Care teamwork, 10, 15, 18–21, 23
evidence-based behavioral interventions, 236–237
major depression, 31, 36, 46–47, 50, 52
psychotic disorders, 105, 109, 113, 120, 122
substance-use disorders, 131, 134, 146, 149–150
caseload management, 21
Catapres. See clonidine
CBT. See cognitive behavioral therapy
celecoxib (Celebrex), 168
Celexa. See citalopram
central sensitization, 163
challenging clinical situations
assessment in, 209–210
behavioral approach to, 218–223
BHP in, 217, 219
case example of, 207, 217–218, 222, 224
clinical impact of, 207–208
common, 208
emotions in, 209–210
environmental conditions of, 213
interventions in, 207–225
patient in, 207, 211–212, 217–220
PC in, 217, 219
PCP in, 217, 219
problematic behaviors in, 211–220
strategies for, 220–222
summarized, 207–208, 225
support needs in, 224–225
treatment in, 218–223
change, stages of, 228–229
chemical dependency counselors, 3
chief complaint
ADHD, 182–184
anxiety and trauma disorders, 78
assessment identifying, 8–9
bipolar disorder, 56
chronic pain, 154, 156–157, 159
major depression, 28–30
psychotic disorders, 102–105
substance-use disorders, 125, 130–131
children
ADHD in, 181–183, 185, 187–188, 192–197, 200
medications for, 194–195
chlordiazepoxide (Librium), 90
chronic diseases
bipolar disorder and, 55, 65
major depression and, 27
chronic pain
assessment of, 154–158
behavioral interventions for, 164, 166–170, 233
BHP and, 157–158, 162, 164–166, 170–173, 176–179
biopsychosocial model of, 163–164, 166
chief complaint of, 154, 156–157, 159
clinical impact of, 153
comorbid disorders with, 159–161
defined, 153
depression and, 160, 171
differential diagnosis of, 158–163
education about, 163–164, 171
fear and, 161
follow-up and adjustment for, 173–178
functional impairments of, 154
goals for, 156–157, 161–162, 164, 170, 172–173, 176–179
health history related to, 154
measures of, 155
medical conditions and, 158–160, 171
medication for, 89, 153, 159, 165, 167–179
chronic pain (continued)
mental health and, 153, 159–160, 170–171, 178
nonpharmacological approaches to, 165, 169–170
pathophysiology of, 155
PC and, 157, 162, 172–173, 177, 179
PCP and, 157–158, 162, 165–170, 172–175, 177–179
physical functioning and, 154
provisional diagnosis of, 161–163
psychosocial functioning and, 154–155
psychosocial interventions for, 166
PTSD and, 160, 169
questionnaire, 156
referrals for, 174
relapse prevention of, 178–179
resources for, 179
safety and, 155, 167
substance-use disorders and, 153, 159–161, 175
suicide and, 155
syndrome, 160
therapeutic alliance for, 166
treatment of, 89, 153, 159, 163–179, 165
types of, 159–160
unspecified, 160
CIDI. See Composite International Diagnostic Interview
citalopram (Celexa), 88, 169
prescribing protocols, 248–249
quick reference, 241
clinical flowchart, 3–4
clinical impact
of ADHD, 181
of anxiety and trauma disorders, 78
of bipolar disorder, 55
of challenging clinical situations, 207–208
of chronic pain, 153
of major depression, 27–28
of psychotic disorders, 101–102
of substance-use disorders, 124–125
clonazepam (Klonopin), 90, 116
prescribing protocols, 260–261
quick reference, 242
clonidine (Catapres), 139, 195
clonidine ER (Kapvay), 195
CM. See care manager
cognitive behavioral therapy (CBT)
for ADHD, 191, 196–197
for anxiety and trauma disorders, 87, 90–91
for bipolar disorder, 69
for chronic pain, 166, 169–170
for depression, 39, 44
for psychotic disorders, 119, 121
cognitive deficits, 103, 113
Collaborative Care team. See also challenging clinical situations;
evidence-based behavioral interventions, for Collaborative Care team; evidence-based psychopharmacology, for Collaborative Care team; team goals
assessment by, 8–15
BHP on, 2–5, 7, 9–10, 15, 17–23
blame among, 209
bond, 229–230
case example of, 10, 15, 18–21, 23
functioning, 6
introduction of, 3–6, 37
overview of, 1
partners, 3
patient on, 1, 3–10, 14–23
PC on, 2, 4–6, 9, 15, 18–22
PCP on, 2–6, 8–11, 14–15, 17–23
principles of, 19
problematic behaviors of, 212–218
roles, 1–3, 6
skills, 3–8
structure, 4
support for, 224–225
tasks, 5, 229–230
tools, 3–8
treatment by, 5, 15–23
workflow, 3–4, 6
communication strategies, 6, 113
Composite International Diagnostic Interview (CIDI), 59
Concerta. See methylphenidate ER conduct disorder, 187 contemplation, 229 continuum of care, 227–228 contraindications, 240 cost, of medications, 240 crisis management, 228, 231–232 culture clash, 6 cyclothymia, 56 Cymbalta. See duloxetine
dosing information (continued)
for antidepressants, 241–242, 247–257
for antipsychotics, 245–246, 275–291
for hypnotic medications, 242–243, 258–264
for miscellaneous medications, 269
for mood stabilizers, 244–246, 270–275
overview of, 239–240
quick reference, 241–246
drug-drug interactions, 240
duloxetine (Cymbalta), 88, 169, 193
prescribing protocols, 249–250
quick reference, 241
dysthymia, 33, 35–36

ECT. See electroconvulsive therapy
education. See also psychoeducation
about chronic pain, 163–164, 171
patient, 15–16, 37–38, 163–164, 171
Effexor. See venlafaxine
Effexor XR. See venlafaxine
Elavil. See amitriptyline
electroconvulsive therapy (ECT), 42
emotions
in challenging clinical situations, 209–210
dysregulated, 220
employment services, 47, 94, 174, 199
endocrine conditions
in ADHD differential diagnosis, 184
in anxiety differential diagnosis, 81
in bipolar disorder differential
diagnosis, 58
in major depression differential
diagnosis, 32
in psychotic disorder differential
diagnosis, 106
in substance-use disorder differential
diagnosis, 133
engagement
in evidence-based behavioral
interventions, 227–235, 237
patient, 170, 221, 227–235, 237
resources, 237
strategies, 229–230
tips, 234–235
environmental conditions, of challenging
situations, 213
Equetro. See carbamazepine extended
release
escitalopram (Lexapro), 88, 169
prescribing protocols, 250
quick reference, 241
evidence-based behavioral interventions,
for Collaborative Care team
BHP and, 227–232, 236–237
case example of, 236–237
continuum of care and, 227–228
core skills in, 227–229
crisis management in, 228, 231–232
engagement in, 227–235, 237
overview of, 227
patient and, 226, 236–237
PC and, 226, 232, 236
PCP and, 226, 229–30, 232, 236
relapse prevention in, 235–236
resources for, 237
specific interventions, 233
therapeutic alliance in, 230–231, 235
treatment in, 232–236
evidence-based psychopharmacology, for
Collaborative Care team. See also
prescribing protocols
antianxiety medications in, 242–243, 258–264
antidepressants in, 241–242, 247–257
BHP and, 238
hypnotic medications in, 242–243, 258–264
overview of, 238–246
patient and, 238
PC and, 238
PCP and, 238
quick reference, 241–246
resources for, 291
evidence-based treatment
for ADHD, 191
for anxiety and trauma disorders, 87
for bipolar disorder, 64, 69
for chronic pain, 165–166
for major depression, 38
overview of, 16–17
for psychotic disorders, 110, 121
for substance-use disorders, 135
exposure treatment, 93
extrapyramidal side effects, 116
family-focused therapy, 69
Fanapt. See iloperidone
FDA indications, 66, 239
fear, chronic pain and, 161
fibromyalgia, 160
fluoxetine (Prozac, Sarafem), 41, 48, 88, 169
prescribing protocols, 250–251
quick reference, 241
follow-up and treatment adjustment
for ADHD, 199–201
for anxiety and trauma disorders, 94–97
for bipolar disorder, 71–74
for chronic pain, 173–178
for major depression, 47–50
overview of, 19–21
for psychotic disorders, 114–120
for substance-use disorders, 147–149
Forfivo XL. See bupropion
functional impairments
of ADHD, 183
of anxiety and trauma disorders, 79
of bipolar disorder, 57
of chronic pain, 154
identification of, 8, 28–29
of major depression, 28–29
of psychotic disorders, 103–104
of substance-use disorders, 128
gabapentin (Neurontin), 138, 141, 167–169
GAD. See generalized anxiety disorder
gastrointestinal conditions
in ADHD differential diagnosis, 184
in anxiety differential diagnosis, 81
in substance-use disorder differential diagnosis, 133
gate control theory, 171
generalized anxiety disorder (GAD), 61, 79, 82–84, 186
generic medications, 240
Geodon. See ziprasidone
grave disability, 104
guanfacine (Tenex), 195
guanfacine ER (Intuniv), 195
Haldol. See haloperidol
hallucinations, 102, 119
haloperidol (Haldol), 111, 117–118, 278–279
harm reduction, for substance-use disorders, 144–145
harming others, thoughts of, 9
health history
of mental health, 8
pain-related, 154
hematologic conditions
in anxiety differential diagnosis, 81
in major depression differential diagnosis, 32
in substance-use disorder differential diagnosis, 133
hospitalization, for psychotic disorders, 114
hydroxyzine pamoate (Vistaril), 88
prescribing protocols, 262
quick reference, 243
hyperalgesia, 174
hypnotic medications
black-box warnings for, 258–264
dosing information for, 242–243, 258–264
in evidence-based psychopharmacology, 242–243, 258–264
monitoring of, 258–264
prescribing protocols for, 258–264
quick reference for, 242–243
hypomania, 56, 83, 186
iatrogenic addiction, 175
ibuprofen (Advil, Motrin), 168
illness anxiety disorder, 160
iloperidone (Fanapt), 111, 117, 279–280
immunological conditions
  in anxiety differential diagnosis, 81
  in bipolar disorder differential diagnosis, 58
  in major depression differential diagnosis, 32
  in psychotic disorder differential diagnosis, 106
  in substance-use disorder differential diagnosis, 133
infectious conditions, 32
initial target dose, 239
insomnia, 89
Internal State Scale (ISS), 71
interpersonal and social rhythm therapy, 69
interpersonal therapy (IPT), 39, 44
intoxication
  in anxiety differential diagnosis, 81
  in bipolar disorder differential diagnosis, 58
  in major depression differential diagnosis, 32
  in psychotic disorder differential diagnosis, 106
Intuniv. See guanfacine ER
Invega. See paliperidone
IPT. See interpersonal therapy
ISS. See Internal State Scale
joint pain, 160
Kapvay. See clonidine ER
Klonopin. See clonazepam
lactation. See breastfeeding
lamotrigine (Lamictal), 49, 66–67, 75
  prescribing protocols, 273–274
  quick reference, 244
Latuda. See lurasidone
learning disabilities, 185–186
Lexapro. See escitalopram
Librium. See chlordiazepoxide
lisdexamfetamine (Vyvanse), 193, 266–267
lithium carbonate (Lithobid), 48, 66–67,
  72, 74–75, 117
  prescribing protocols, 274–275
  quick reference, 244
Lithobid. See lithium carbonate
lorazepam (Ativan), 90
  prescribing protocols, 262–263
  quick reference, 243
low back pain, 160
lurasidone (Latuda), 66–67, 111
  prescribing protocols, 280–281
  quick reference, 245
Lyrica. See pregabalin
maintenance, of change, 229
maintenance treatment
  for anxiety and trauma disorders, 98
  for bipolar disorder, 63, 66–67, 74–75
  for major depression, 51
major depression
  adolescent, 53
  assessment of, 28–31, 33
  behavioral interventions for, 39–40, 44, 49, 233
  BHP and, 30–31, 36, 39, 44–47, 49–50, 52
  case example of, 31, 36, 46–47, 50, 52
  chief complaint identified in, 28–30
  chronic diseases and, 27
  chronic pain and, 160
  clinical impact of, 27–28
  comorbid disorders with, 33
  differential diagnosis and, 32–36, 60, 83, 186
  follow-up and adjustment for, 47–50
  functional impairment of, 28–29
  goals for, 30, 35–36, 45–46, 49–50
  medication for, 38–43, 48, 241–242, 247–257
  patient and, 30–31, 35–37, 45–50, 52–54
  PC and, 30–31, 36, 46–47, 52
  PCP and, 29–31, 36–37, 39–43, 45–49, 52
  PHQ-9 screening for, 7, 33
  physical/somatic symptoms of, 28–29
  provisional diagnosis of, 32, 35–36
psychoeducation about, 37–38
psychological symptoms of, 28
psychosocial interventions for, 38, 43, 51
with psychotic features, 47, 107, 117
referrals for, 47–48
relapse prevention of, 51–52
resources for, 53–54
safety and, 28–30, 38
substance-use disorders and, 32–33
suicide and, 29–31, 47
violence and, 30
major neurocognitive disorder. See
dementia
malingering, 221
mania
acute, 63, 66–67
conditions mimicking, 56
hypomania, 56, 83, 186
psychosis and, 108
treatment of, 63, 66, 245–246
MAT. See modular anxiety treatment
maximum dose, 239
MDQ. See Mood Disorder Questionnaire
measurement-based practice, 19, 171, 237
measurements
assessment, 8
chronic pain, 155
defined, 7
of goals, 235, 237
mechanism of action, 239
medical conditions
in ADHD differential diagnosis, 184
in anxiety differential diagnosis, 81
chronic pain and, 158–160, 171
in major depression differential
diagnosis, 32, 35
mania and, 56
multiple, 220
psychotic disorders and, 101, 106–107, 117
ruled out, 10
in substance-use disorder differential
diagnosis, 133
medication treatment. See also evidence-based psychopharmacology, for Collaborative Care team;
prescribed medications; side effects
for ADHD, 191–196, 198–202, 264–269
for anxiety and trauma disorders,
87–90, 94–99, 242–243, 258–264
augmentation of, 48, 65, 71
for bipolar disorder, 64–76, 89, 245–246
breastfeeding and, 42, 118, 240,
248–257, 259–267, 269, 271–272,
274–275, 277–282, 284–286,
288–289, 291
for children, 194–195
for chronic pain, 89, 153, 159, 165,
167–179
cost of, 240
for major depression, 38–43, 48,
241–242, 247–257
ongoing management of, 51, 74–75, 95,
120, 174, 199–200
overview of, 17
pregnancy and, 42, 118, 248–257,
259–267, 269–272, 274–275,
for psychotic disorders, 110–122,
245–246, 275–277
safe, 42
for substance-use disorders, 135,
138–142, 145, 147–148
warnings/precautions for, 240, 246
meloxicam (Mobic), 168
mental health
chronic pain and, 153, 159–160,
170–171, 178
in differential diagnosis, 11, 13–14
history, 8
physical symptoms and, 216
substance-use disorders and, 32–33, 58,
61, 132–133
metabolic conditions
in anxiety differential diagnosis, 81
in bipolar disorder differential
diagnosis, 58
metabolic conditions (continued)
in major depression differential diagnosis, 32
in psychotic disorder differential diagnosis, 106
in substance-use disorder differential diagnosis, 133
metabolic side effects, 116
metabolism, 240
Metadate CD. See methylphenidate
Metadate ER. See methylphenidate
methadone, 140
methylphenidate (Ritalin, Metadate ER, Methylin ER, Ritalin SR, Metadate CD, Ritalin LA, Daytrana-patch, Quillivant XR), 193–194, 267–269
methylphenidate ER (Concerta), 191, 193, 267–268
MI. See Motivational Interviewing
migraine, 160
mindfulness, 91
Minipress. See prazosin
mirtazapine (Remeron), 39–41, 88
prescribing protocols, 251–252
quick reference, 241
miscellaneous medications, prescribing protocols for, 269
mistrust, 113
mixed receptor antidepressants, 169
Mobic. See meloxicam
modular anxiety treatment (MAT), 91–93
monitoring
ADHD medications, 264–269
antianxiety medications, 258–264
antidepressants, 247–257
antipsychotics, 121, 276–280, 281, 283–285, 287, 289–290
declared, 239
hypnotic medications, 258–264
miscellaneous medications, 269
mood stabilizers, 270, 272–274
Mood Disorder Questionnaire (MDQ), 59
mood disorders, 11. See also bipolar disorder; major depression
mood stabilizers, 48, 64–65, 69
black-box warnings for, 270, 272–274
dosing information for, 244–246, 270–275
monitoring of, 270, 272–274
prescribing protocols for, 270–275
quick reference for, 244–246
side effects of, 270–274
warnings/precautions, 246
Motivational Interviewing (MI), 40, 65
resources, 237
for substance-use disorders, 134, 136–137, 144
Motrin. See ibuprofen
muscle relaxants, 167
musculoskeletal pain, 159
nabumetone (Relafen), 168
naloxone, 138, 141
naltrexone, 138–141
naproxen (Naprosyn), 168
naproxen sodium (Aleve), 168
negative symptoms, 103, 119
neuroleptic malignant syndrome (NMS), 116–117
neurological conditions
in ADHD differential diagnosis, 184
in anxiety differential diagnosis, 81
in bipolar disorder differential diagnosis, 58
in major depression differential diagnosis, 32
in psychotic disorder differential diagnosis, 106
in substance-use disorder differential diagnosis, 133
Neurontin. See gabapentin
neuropathic pain, 155, 169
NMS. See neuroleptic malignant syndrome
nociceptive pain, 155
nonopioid analgesics, 165, 167–168
nonpharmacological approaches, to chronic pain, 165, 169–170
nonsteroidal anti-inflammatory drugs (NSAIDs), 165, 167
nortriptyline (Pamelor), 41–42
prescribing protocols, 252–253
quick reference, 241
NSAIDs. See nonsteroidal
anti-inflammatory drugs

obsessive compulsive disorder (OCD), 79, 82–84, 186
off-label indications, 239
olanzapine (Zyprexa), 48, 111, 117–118
prescribing protocols, 281–282
quick reference, 245
olanzapine and fluoxetine (Symbyax), 66–67, 111, 283–284
Oleptro. See trazodone
oncologic conditions, 32
on-going training, 235
opioid use
disorders, 124, 126–129, 132–133, 135, 139–141, 144
harm reduction ideas for, 144
overdose from, 175
organ system damage, 127
overdose, 128–129, 175

pain. See also chronic pain
catastrophizing, 161
suffering vs., 171
pain-related health history, 154
paliperidone (Invega), 111, 117, 284–285
Pamelor. See nortriptyline
panic disorder, 79, 82–84, 160
paranoia, 113
parent behavioral training (PBT), 197
paroxetine (Paxil, Paxil CR, Pexeva), 41, 88
prescribing protocols, 253–254
quick reference, 242
partial agonists, 140
partners, in team building, 3
passive coping, 161
patient
ADHD and, 183–184, 188–190, 198–202
anxiety and trauma disorders and, 80–81, 85, 93–94, 96–97, 99
bipolar disorder and, 57–58, 62–63, 70, 72–73, 76
blaming of, 210
care centered on, 236
in challenging clinical situations, 207, 211–212, 217–220
on Collaborative Care team, 1, 3–10, 14–23
difficult, 208
education, 15–16, 37–38, 163–164, 171
engagement, 170, 221, 227–235, 237
evidence-based behavioral interventions and, 226, 236–237
evidence-based psychopharmacology and, 238
goals centered on, 170
information to share with, 6
major depression and, 30–31, 35–37, 45–50, 52–54
problematic behaviors of, 211–212, 218–220
provider’s problematic behaviors affecting, 214–216
psychotic disorders and, 105, 108–109, 113, 119–120, 122
substance-use disorders and, 130–131, 133–134, 146, 148–150
team approach introduced to, 3–6
Patient Health Questionnaire (PHQ-9), 7, 33, 71
Paxil. See paroxetine
Paxil CR. See paroxetine
PBT. See parent behavioral training
PC. See psychiatric consultant
PCP. See primary care provider
PDSA. See Plan-Do-Study-Act
peer support specialist, 75
pelvic pain, 159
periphery neuropathic pain, 159–160
perphenazine (Trilafon), 111, 285–286
persistent depressive disorder. See
dysthymia
Pexeva. See paroxetine
pharmacogenomics, 240
pharmacokinetics, 239
pharmacotherapy. See medication
treatment
phototherapy, 38
PHQ-9. See Patient Health Questionnaire
physical functioning, chronic pain and,
154
physical rehabilitation, 165, 169
physical/somatic symptoms
of ADHD, 183
of anxiety and trauma disorders, 78–79
of bipolar disorder, 56–57
identification of, 8, 28–29
of major depression, 28–29
mental health and, 216
of psychotic disorders, 103
of substance-use disorders, 126
physiological relaxation skills, 91
Plan-Do-Study-Act (PDSA), 7
population-based care, 236
postpartum depression, 33, 56
posttraumatic stress disorder (PTSD)
chronic pain and, 160, 169
differential diagnosis and, 34, 61,
82–84, 160, 186–187
physical and psychological symptoms
of, 79
prazosin (Minipress), 88, 169
prescribing protocols, 269
quick reference, 243
precautions, medication-related, 240
precontemplation, 228–229
pregabalin (Lyrica), 167–169
pregnancy
medication and, 42, 118, 248–257,
259–266, 269–272, 274–275,
psychosis in, 118
premenstrual dysphoric disorder, 35
preparation, 229
prescribed medications
in ADHD differential diagnosis, 184
in anxiety differential diagnosis, 82
in bipolar disorder differential
diagnosis, 58
in major depression differential
diagnosis, 33, 35
in psychotic disorder differential
diagnosis, 106
safety of, 42, 68
prescribing protocols. See also black-box
warnings; dosing information;
monitoring
ADHD medication, 264–269
alprazolam, 258–259
antianxiety medication, 258–264
antidepressant, 247–257
antipsychotic, 275–291
aripiprazole, 275–277
asenapine, 277–278
atomoxetine, 264–265
bupropion, 247–248
buspirone, 259–260
carbamazepine extended release,
270–271
citalopram, 248–249
clonazepam, 260–261
dextroamphetamine/amphetamine,
265–266
diazepam, 261–262
divalproex sodium, 271–273
duloxetine, 249–250
escitalopram, 250
fluoxetine, 250–251
hydroxyzine pamoate, 262
hypnotic medication, 258–264
iloperidone, 279–280
lamotrigine, 273–274
lisdexamfetamine, 266–267
lithium, 274–275
lorazepam, 262–263
lurasidone, 280–281
methylphenidate, 267–269
mirtazapine, 251–252
miscellaneous medication, 269
mood stabilizers, 270–275
nortriptyline, 252–253
olanzapine, 281–282
olanzapine and fluoxetine, 283–284
overview of, 238–240
paliperidone, 284–285
paroxetine, 253–254
perphenazine, 285–286
prazosin, 269
quetiapine, 286–288
risperidone, 288–289
sertraline, 254–255
temazepam, 263–264
trazodone, 255–256
venlafaxine, 256–257
ziprasidone, 290–291

primary care provider (PCP)
ADHD and, 184, 188–196, 198–202
anxiety and trauma disorders and, 80–81, 85–99
bipolar disorder and, 57–58, 62, 66–68, 70–72, 76
in challenging clinical situations, 217, 219
chronic pain and, 157–158, 162, 165–170, 172–175, 177–179
on Collaborative Care team, 2–6, 8–11, 14–15, 17–23
evidence-based behavioral interventions and, 226, 229–230, 232, 236
evidence-based psychopharmacology and, 238
major depression and, 29–31, 36–37, 39–43, 45–49, 52
measurement-based practice and, 19
psychotic disorders and, 101, 105, 108–118, 120–122
substance-use disorders and, 130–131, 134–143, 146–150
suicide assessment by, 29–30
problem solving therapy (PST), 39, 44
problematic behaviors in challenging clinical situations, 211–220
effects of, 214–216
patient's, 211–212, 218–220
provider's, 212-218
progress review, 7
propranolol, 116
provider, problematic behaviors of, 212–218
provisional diagnosis of ADHD, 188–189
disorders, 81–85
in assessment, 10–15
of bipolar disorder, 58–63
of chronic pain, 161–163
of major depression, 32, 35–36
of psychotic disorders, 106, 108
of substance-use disorders, 131, 133
Prozac. See fluoxetine
PST. See problem solving therapy
psychiatric consultant (PC)
ADHD and, 184, 189, 198, 200–202
anxiety and trauma disorders and, 80, 85, 93–94, 97, 99
bipolar disorder and, 57–58, 62, 70, 72–73, 76
in challenging clinical situations, 217, 219
chronic pain and, 157, 162, 172–173, 177, 179
on Collaborative Care team, 2, 4–6, 9, 15, 18–22
evidence-based behavioral interventions and, 226, 232, 236
evidence-based psychopharmacology and, 238
major depression and, 30–31, 36, 46–47, 52
measurement-based practice and, 19
psychotic disorders and, 105, 108, 113, 117, 120, 122
substance-use disorders and, 131, 134, 146, 149–150
psychiatric disorders, comorbid. See comorbid psychiatric disorders and psychological difficulties
psychiatric hospitalization, 114
psychoeducation
about ADHD, 190
about anxiety and trauma disorders, 86
about bipolar disorder, 66
about chronic pain, 171
engagement and, 234
psychoeducation (continued)
  about major depression, 37–38
  about psychotic disorders, 109–110
psychological difficulties, comorbid. See
comorbid psychiatric disorders
and psychological difficulties
psychological symptoms
  of ADHD, 182–183
  of anxiety and trauma disorders, 78–79
  of bipolar disorder, 56
  identification of, 8
  of major depression, 28
  of psychotic disorders, 102–103
  of substance-use disorders, 126
psychopharmacology. See evidence-based
psychopharmacology, for
Collaborative Care team
psychosocial functioning, chronic pain
and, 154–155
psychosocial interventions
  for ADHD, 191–192, 197
  for anxiety and trauma disorders, 87
  for bipolar disorder, 64, 68–69, 75
  for chronic pain, 166
  for major depression, 38, 43, 51
  for psychotic disorders, 110
  for substance-use disorders, 135, 143–145
psychotherapeutic approaches
  for bipolar disorder, 69
  continuum of care and, 227–228
psychotic disorders
  assessment of, 102–105
  behavioral interventions for, 110, 112, 119, 121, 233
  BHP and, 105, 108–110, 112–113, 118–120, 122
  breastfeeding and, 118
  case example of, 105, 109, 113, 120, 122
  chief complaint of, 102–105
  clinical impact of, 101–102
  communication strategies for, 113
  comorbid disorders with, 108
  differential diagnosis of, 106–109
  follow-up and adjustment for, 114–120
  functional impairment of, 103–104
  goals for, 105, 108, 113, 119–122
hospitalization for, 114
medical conditions and, 101, 106–107, 117
medical work-up for, 106
medication for, 110–122, 245–246, 275–277
patient and, 105, 108–109, 113, 119–120, 122
PC and, 105, 108, 113, 117, 120, 122
PCP and, 101, 105, 108–118, 120–122
physical/somatic symptoms of, 103
pregnancy and, 118
provisional diagnosis of, 106, 108
psychoeducation about, 109–110
psychological symptoms of, 102–103
psychosocial interventions for, 110
referrals for, 114
relapse prevention of, 120–122
resources for, 122
safety and, 104
substance-use disorders and, 106–107, 117–118
suicide and, 104
types of, 107
violence and, 104
psychotic features
  bipolar disorder with, 107, 117
  in differential diagnosis, 12
  major depression with, 47, 107, 117
PTSD. See posttraumatic stress disorder
QTC interval prolongation, 117
quetiapine (Seroquel IR, Seroquel XR), 48, 66–67, 111, 117–118
prescribing protocols, 286–288
quick reference, 246
Quillivant XR. See methylphenidate

rapid cycling bipolar disorder, 67
rating scales, ADHD, 185
references, 22
referrals, for additional services
  for ADHD, 199
  for anxiety and trauma disorders, 94
for bipolar disorder, 71
for chronic pain, 174
for major depression, 47–48
overview of, 20
for psychotic disorders, 114
for substance-use disorders, 147
registry, 7–8
Relafen. See nabumetone
relapse prevention
of ADHD, 201–202
of anxiety and trauma disorders, 97–99
of bipolar disorder, 74–76
of chronic pain, 178–179
in evidence-based behavioral interventions, 235–236
of major depression, 51–52
overview of, 21–23
of psychotic disorders, 120–122
of substance-use disorders, 149–150
Remeron. See mirtazapine
resources
ADHD, 202
anxiety and trauma disorder, 99
bipolar disorder, 76–77
chronic pain, 179
engagement, 237
evidence-based behavioral intervention, 237
evidence-based psychopharmacology, 291
major depression, 53–54
overview of, 22
psychotic disorder, 122
substance-use disorder, 151
respiratory conditions
in ADHD differential diagnosis, 184
in anxiety differential diagnosis, 81
in major depression differential diagnosis, 32
in substance-use disorder differential diagnosis, 133
respiratory depression, 175
Restoril. See temazepam
risperidone (Risperdal), 111, 117–118
prescribing protocols, 288–289
quick reference, 246
Ritalin. See methylphenidate
Ritalin LA. See methylphenidate
Ritalin SR. See methylphenidate
safety
ADHD and, 192
anxiety and trauma disorders and, 79–80, 86
assessment for, 9, 13
bipolar disorder and, 57
chronic pain and, 155, 167
major depression and, 28–30, 38
planning, 17
in prescribing medication, 42, 68
psychotic disorders and, 104
substance-use disorders and, 128–129
Saphris. See asenapine
Sarafem. See fluoxetine
schizoaffective disorder, 107, 117, 121
schizophrenia, 101, 107, 121
seasonal affective disorder, 33, 38
secondary gains, 161
selective serotonin reuptake inhibitors (SSRIs), 39–42, 48, 88, 169
self-care, 224–225
self-harm, 9, 155
self-help books, 22, 179
Seroquel IR, Seroquel XR. See quetiapine
serotonergic antidepressants, 42, 87–88
serotonin syndrome, 42
serotonin-norepinephrine reuptake inhibitors (SNRIs), 39–41, 48, 167, 169, 194
sertraline (Zoloft), 88, 169
prescribing protocols, 254–255
quick reference, 242
sexual side effects, 43
shared goals and tasks, 229–231
shared workflow, of Collaborative Care team, 3–4, 6
SI. See suicidal ideation
side effects, 72, 194, 269
of ADHD medications, 264, 266–268
of antianxiety medications, 258–263
of antidepressants, 42–43, 247–257
of antipsychotics, 102, 115–117, 276–283, 285–290
side effects (continued)
  common, 239
  extrapyramidal, 116
  metabolic, 116
  of mood stabilizers, 270–274
  overview of, 239
  sexual, 43
skills
  accountable practice, 7
  Collaborative Care, 3–8
  core, 227–229
  registry, 7–8
  team functioning, 6
  training, 3
sleep medications. See hypnotic medications
SNRIs. See serotonin-norepinephrine reuptake inhibitors
social anxiety disorder/social phobia, 79, 82–84
Soma. See carisoprodol
somatic symptom disorders, 34, 160
somatic symptoms. See physical/somatic symptoms
splitting, 211–215, 220
SSRIs. See selective serotonin reuptake inhibitors
stages of change, 228–229
starting dose, 239
stepped-care approach, 19
stimulant use, 49
  ADHD and, 191–194, 198–199
  disorders, 124, 126–127, 129, 132–133, 141, 144
  harm reduction ideas for, 144
Strattera. See atomoxetine
Suboxone. See buprenorphine/naloxone substance/medication-induced psychotic disorder, 107, 117
substance-use disorders (SUD)
  ADHD and, 184, 191
  alcohol, 35, 124–128, 132–133, 135, 137–139, 144
  assessment of, 125–132
  behavioral indicators of, 126
  behavioral interventions for, 135, 141, 147, 233
  BHP and, 130–131, 134–136, 143–146, 148–150
  bipolar disorder and, 58, 61
  cannabis, 124, 126–127, 129–130, 132, 141
  case example of, 131, 134, 146, 149–150
  chief complaint of, 125, 130–131
  chronic pain and, 153, 159–161, 175
  clinical impact of, 124–125
  differential diagnosis and, 12, 32–35, 61, 81–84, 131–134
  follow-up and adjustment for, 147–149
  functional impairments of, 128
  goals for, 130–131, 133–134, 146, 149–150
  harm reduction for, 144–145
  major depression and, 32–33
  medical conditions in, 133
  medication for, 135, 138–142, 145, 147–148
  mental health and, 32–33, 58, 61, 132–133
  MI for, 134, 136–137, 144
  opioid, 124, 126–129, 132–133, 135, 139–141, 144
  patient and, 130–131, 133–134, 146, 148–150
  PC and, 131, 134, 146, 149–150
  PCP and, 130–131, 134–143, 146–150
  physical/somatic symptoms of, 126
  provisional diagnosis of, 131, 133
  psychological symptoms of, 126
  psychosocial interventions for, 135, 143–145
  psychotic disorders and, 106–107, 117–118
  referrals for, 147
  relapse prevention of, 149–150
  resources for, 151
  ruled out, 10, 32–33, 58
  safety and, 128–129
  stimulant, 124, 126–127, 129, 132–133, 141, 144
  treatment of, 134–150
  types of, 132
  subsyndromal symptoms, 65
SUD. See substance-use disorders
suffering, pain vs., 171
suicidal ideation (SI), 80, 128
suicide
alcohol use and, 128
assessing for, 9, 29–31
bipolar disorder and, 57
chronic pain and, 155
major depression and, 29–31, 47
psychotic disorders and, 104
strategies and, 220
support, in challenging clinical situations, 224–225
Symbyax. See olanzapine and fluoxetine
symptoms. See also physical/somatic
symptoms; psychological
assessment of, 8, 11
negative, 103, 119
progress measured for, 235
subsyndromal, 65
tardive dyskinesia (TD), 116
TCAs. See tricyclic antidepressants
TD. See tardive dyskinesia
team. See Collaborative Care team
team goals
for ADHD, 183–184, 188–189, 198, 200, 202
for anxiety and trauma disorders, 80, 84–85, 93, 96–97, 99
assessment and, 9, 11–15
for bipolar disorder, 57, 62, 70, 72, 76
for chronic pain, 156–157, 161–162,
164, 170, 172–173, 176–179
for major depression, 30, 35–36, 45–46,
49–50
measured, 235, 237
patient-centered, 170
for psychotic disorders, 105, 108, 113,
119–122
setting, 16, 235
sharing, 6–7, 229–231
for substance-use disorders, 130–131,
133–134, 146, 149–150
for treatment, 16–20, 22
team-building process, 1, 3
temazepam (Restoril), 90
prescribing protocols, 263–264
quick reference, 243
Tenex. See guanfacine
therapeutic alliance
for chronic pain, 166
in evidence-based behavioral
interventions, 230–231, 235
time limited care, 234
tobacco use, 108
tools, Collaborative Care, 3–8
toxins, 106
training, skills, 3
trauma disorders. See anxiety and trauma
disorders
trazodone (Desyrel, Oleptro), 41, 43
prescribing protocols, 255–256
quick reference, 243
treatment. See also behavioral
interventions; biological
treatment; completion, of
treatment; evidence-based
treatment; follow-up and
treatment adjustment; medication
treatment; psychosocial
interventions
of ADHD, 190–202, 264–269
of anxiety and trauma disorders, 86–99,
242–243, 258–264
of bipolar disorder, 63–76, 89, 245–246
in challenging clinical situations,
218–223
of chronic pain, 89, 153, 159, 163–179,
165
by Collaborative Care team, 5, 15–23
in continuum of care, 228
environment, 213
in evidence-based behavioral
interventions, 232–236
exposure, 93
goals, 16–20, 22
initiation, 15–16
maintenance, 51, 63, 66–67, 74–75, 98
of major depression, 36–52, 241–242,
247–257
of mania, 63, 66, 245–246
multiple options for, 235
treatment (continued)
pitch made for, 234
of psychotic disorders, 109–122, 245–246, 275–277
resistance, 117
of substance-use disorders, 134–150
timeline, 5
tricyclic antidepressants (TCAs), 41–42, 167, 169
tri-iodothyronine, 48
Trilafon. See perphenazine
trust, building, 6
typical dosage range, 239

Valium. See diazepam
venlafaxine (Effexor, Effexor XR), 41, 88, 169, 193
prescribing protocols, 256–257
quick reference, 242
violence
major depression and, 30
psychotic disorders and, 104
Vistaril. See hydroxyzine pamoate
Voltaren. See diclofenac
Vyvanse. See lisdexamfetamine

warm handoff, 3
warnings/precautions, 240, 246
Web resources
ADHD, 202
bipolar disorder, 76–77
chronic pain, 179
evidence-based behavioral intervention, 237
evidence-based psychopharmacology, 291
major depression, 53–54
overview of, 22
psychotic disorder, 122
substance-use disorder, 151
Wellbutrin. See bupropion
Wellbutrin SR. See bupropion
Wellbutrin XL. See bupropion
widespread pain, 159
withdrawal
from alcohol, 137
in anxiety differential diagnosis, 81
in bipolar disorder differential diagnosis, 58
in major depression differential diagnosis, 32
in psychotic disorder differential diagnosis, 106
workflow, of Collaborative Care team, 3–4, 6
workforce development, 235

Xanax. See alprazolam
Xanax XR. See alprazolam
XR naltrexone IM, 138
ziprasidone (Geodon), 111, 117, 290–291
Zoloft. See sertraline
zolpidem (Ambien), 243
Zyban. See bupropion
Zyprexa. See olanzapine